BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that data from a phase I clinical trial evaluating weekly dosing of SGN-35 will be reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting being held May 29 to June 2, 2009 in Orlando, Florida.
